<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7763119\results\search\disease\results.xml">
  <result pre="quinoline scaffolds derivatives with improved anticancer activity against breast and" exact="colon cancer" post="cell lines and P-glycoprotein, cytochrome p450 enzyme activity prediction"/>
  <result pre="scaffolds derivatives with improved anticancer activity against breast and colon" exact="cancer" post="cell lines and P-glycoprotein, cytochrome p450 enzyme activity prediction"/>
  <result pre="and pendant group on the polymer chains. PEGylated quinoline breast" exact="colon cancer" post="P-glycoprotein cytochrome P450 enzyme 1. Introduction A library of"/>
  <result pre="pendant group on the polymer chains. PEGylated quinoline breast colon" exact="cancer" post="P-glycoprotein cytochrome P450 enzyme 1. Introduction A library of"/>
  <result pre="using the Alamar blue (AB) assay (in the case of" exact="leukemia" post="cells) for their antiproliferative activity in vitro against 2"/>
  <result pre="leukemia cells) for their antiproliferative activity in vitro against 2" exact="cancer" post="cell lines: SW620, MD468, and MD468-2 were all colon"/>
  <result pre="2 cancer cell lines: SW620, MD468, and MD468-2 were all" exact="colon cancer" post="cell lines obtained from the American Tissue Culture Collection"/>
  <result pre="cancer cell lines: SW620, MD468, and MD468-2 were all colon" exact="cancer" post="cell lines obtained from the American Tissue Culture Collection"/>
  <result pre="compounds 3aâ€&quot;3i and 4aâ€&quot;4i. Â SrNo. MDA MD 468 (breast" exact="cancer" post="cell line) SW480Â (colon cancer cell) Before PEGylating(3aâ€&quot;3i) AfterPEGylating(4aâ€&quot;4i)"/>
  <result pre="SrNo. MDA MD 468 (breast cancer cell line) SW480Â (colon" exact="cancer" post="cell) Before PEGylating(3aâ€&quot;3i) AfterPEGylating(4aâ€&quot;4i) Improvement in efficacy (fold) Before"/>
  <result pre="compounds were tested via AB assay (in the case of" exact="leukemia" post="cells) for their antiproliferative activity in vitro against 2"/>
  <result pre="leukemia cells) for their antiproliferative activity in vitro against 2" exact="cancer" post="cell lines: SW620, MD468, and MD468-2 were all colon"/>
  <result pre="2 cancer cell lines: SW620, MD468, and MD468-2 were all" exact="colon cancer" post="cell lines obtained from the ATCC. MD468 is a"/>
  <result pre="cancer cell lines: SW620, MD468, and MD468-2 were all colon" exact="cancer" post="cell lines obtained from the ATCC. MD468 is a"/>
  <result pre="4aâ€&quot;4i exhibited potent antiproliferative activity against theSW620, MD468, and MD468-2" exact="colon cancer" post="cell lines. This implied that after PEGylation, the anticancer"/>
  <result pre="exhibited potent antiproliferative activity against theSW620, MD468, and MD468-2 colon" exact="cancer" post="cell lines. This implied that after PEGylation, the anticancer"/>
  <result pre="exhibited the highest activity against the SW620, MD468, and MD468-2" exact="colon cancer" post="cell lines and had IC50 values of 8.5 nM/mL"/>
  <result pre="the highest activity against the SW620, MD468, and MD468-2 colon" exact="cancer" post="cell lines and had IC50 values of 8.5 nM/mL"/>
  <result pre="and also possessed the highest anticancer activity against the SW620" exact="colon cancer" post="cell line. Compounds 4g and 4b showed lower activity"/>
  <result pre="also possessed the highest anticancer activity against the SW620 colon" exact="cancer" post="cell line. Compounds 4g and 4b showed lower activity"/>
  <result pre="be a highly-potent candidate against the SW620, MD468, and MD468-2" exact="colon cancer" post="cell lines than the existing armory of anticancer drugs"/>
  <result pre="a highly-potent candidate against the SW620, MD468, and MD468-2 colon" exact="cancer" post="cell lines than the existing armory of anticancer drugs"/>
  <result pre="living cells. Cells: For the initial screen of A549, the" exact="lung cancer" post="cells were used. Positive hits were then used to"/>
  <result pre="cells. Cells: For the initial screen of A549, the lung" exact="cancer" post="cells were used. Positive hits were then used to"/>
  <result pre="IC50 value was calculated. SW620, MD468, and MD468-2 were all" exact="colon cancer" post="cell lines obtained from the ATCC. MD468 is a"/>
  <result pre="value was calculated. SW620, MD468, and MD468-2 were all colon" exact="cancer" post="cell lines obtained from the ATCC. MD468 is a"/>
  <result pre="mutation. The effects of all of the new compounds on" exact="colon cancer" post="cell lines SW620, MD468, and MD468-2, were observed and"/>
  <result pre="The effects of all of the new compounds on colon" exact="cancer" post="cell lines SW620, MD468, and MD468-2, were observed and"/>
  <result pre="generate killed cells. Figure 1 Effect of compounds 4aâ€&quot;4i in" exact="colon cancer" post="line (SW620). Figure 2 Effect of control standard anticancer"/>
  <result pre="killed cells. Figure 1 Effect of compounds 4aâ€&quot;4i in colon" exact="cancer" post="line (SW620). Figure 2 Effect of control standard anticancer"/>
  <result pre="C-3 position exhibited good to moderate anticancer activity against the" exact="cancer" post="cell lines. In contrast, the quinoline scaffold that amalgamated"/>
  <result pre="showed excellent anticancer activity against the SW620, MD468, and MD468-2" exact="colon cancer" post="cell lines. However, the imine derivatives of the PEGylated"/>
  <result pre="excellent anticancer activity against the SW620, MD468, and MD468-2 colon" exact="cancer" post="cell lines. However, the imine derivatives of the PEGylated"/>
 </snippets>
</snippetsTree>
